The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

By: Newsfile

SmallCaps Daily Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side Effects

New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual technology, designed to rapidly deliver therapeutics while bypassing the gastrointestinal tract and liver. SmallCaps Daily sat down with CEO Kraig Higginson to learn more about Aspire's mission to enhance existing drugs-from fast-acting aspirin and ED treatments to hormonal therapies and supplements-while reducing side effects and improving patient outcomes. With multiple product launches expected this year and a focus on strategic licensing partnerships with major pharmaceutical players, Aspire Biopharma is positioning itself at the forefront of a $100 billion industry primed for innovation.

To read the full article, visit:
https://smallcapsdaily.com/aspire-biopharma-ceo-interview-disrupting-drug-delivery-with-sublingual-tech

About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time.

For more information, please visit www.aspirebiolabs.com.

Contact Information
SmallCapsDaily
info@smallcapsdaily.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243840

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.